| Literature DB >> 28351377 |
Susanne Röll1, Stefan Härtle2, Thomas Lütteke1,3, Bernd Kaspers1, Sonja Härtle4,5.
Abstract
BACKGROUND: Type I interferons are major players against viral infections and mediate their function by the induction of Interferon regulated genes (IRGs). Recently, it became obvious that these cytokines have a multitude of additional functions. Due to the unique features of the chickens' immune system, available data from mouse models are not easily transferable; hence we performed an extensive analysis of chicken IRGs.Entities:
Keywords: Chicken; Expression profile; Half-life; IFNα; IRG
Mesh:
Substances:
Year: 2017 PMID: 28351377 PMCID: PMC5371264 DOI: 10.1186/s12864-017-3641-6
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1Pharmacokinetic profile of recombinant ChIFNα after i.v. injection. Three chickens were treated i.v. with a single dose of recChIFNα (1x107Units for the biggest bird and a direct proportional weight adjusted dose for the others). Plasma was taken at the indicated time points, and the amount of biological active type I IFN was determined using an IFN reportergene assay
Fig. 2IFN treatment for the microarray experiment. a Four groups of chickens (n = 6 per group) received recChIFNα as indicated in the experimental scheme. b At the indicated time points animals were sacrificed and the plasma concentration of biologically active type I IFN was measured using an IFN reporter gene assay. Shown are group mean and individual IFN concentrations
Fig. 3Microarray analysis after IFN injection. a “R” based heat map of spleen and lung tissue: Probes are labeled by group membership and animal number (1-4). Data sets with an unusual assignment which deviates from the rest of the group are boxed. b Venn diagram for the comparison of microarray and in silico analysis: Shown are the intersections of significantly regulated genes 3 h after IFN injection between spleen (red), lung (blue) tissue and the “common IRGs” (green), identified by database analysis. c Intersections of IRGs in spleen and lung at different time points after IFN injection: Numbers indicate array-based significantly regulated genes; numbers in brackets represent “common IRGs”
Number of differentially expressed genes after IFN injection with a FC ≤ -2 or ≥ 2
| # of genes | ||||
|---|---|---|---|---|
| Spleen | IFN (3 h) | 1869 | + | 871 |
| - | 998 | |||
| IFN (6 h) | 852 | + | 316 | |
| - | 536 | |||
| IFN (9 h) | 665 | + | 257 | |
| - | 408 | |||
| Lung | IFN (3 h) | 945 | + | 685 |
| - | 260 | |||
| IFN (6 h) | 435 | + | 372 | |
| - | 63 | |||
| IFN (9 h) | 611 | + | 489 | |
| - | 122 | |||
Top 30 of genes with the highest or least changes in mRNA abundance in spleen (A) and lung (B). The scanned region for promotor elements ranged from 6 kb upstream to 1 kb downstream of the first exon
| Gene symbol | Gene description | Maximal FC | Timepoint of maximal FC | cIRG | Expression in lung | # of Promotor elements (ISRE/GAS) |
|---|---|---|---|---|---|---|
| A) | ||||||
| PTX3 | Pentraxin related gene, rapidly induced by IL1 beta | 685 | 3 h | x | x | 0/7 |
| SFTPA1 | Surfactant, pulmonary-associated protein A1 | −436 | 9 h | x | - | 0/12 |
| LOC396260 | Mature avidin | 384 | 9 h | - | x | 1/7 |
| IL6 | Interleukin-6 | 186 | 3 h | x | x | 0/8 |
| LAO | L-amino-acid oxidase precursor (Interleukin-4 induced 1) | 169 | 3 h | - | x | 0/7 |
| K203 | Chicken chemokine (C-C motif) L i 3 | 145 | 3 h | - | x | 0/6 |
| LL | Lung lectin | −140 | 9 h | - | - | 0/12 |
| PSCA | Prostate stem cell antigen | −124 | 9 h | - | - | 0/12 |
| KCNA1 | Potassium voltage-gated channel, shaker-related subfamily, member 1 | −69 | 3 h | - | - | 0/5 |
| LYG2 | Lysozyme G-like 2 | 62 | 3 h | - | x | 0/6 |
| CSF3 | Colony stimulating factor 3 | 58 | 3 h | x | x | 0/3 |
| NEFH | Neurofilament, heavy polypeptide | −56 | 3 h | - | - | 0/5 |
| CMBL | Carboxymethylenebutenolidase homolog | 44 | 3 h | - | x | 0/12 |
| GCH1 | GTP cyclohydrolase 1 | 43 | 3 h | x | x | 0/9 |
| FSHR | Follicle stimulating hormone receptor | −39 | 3 h | - | - | 0/5 |
| ZPD | Zona pellucida protein D | 38 | 3 h | - | - | 0/13 |
| IRG1 | Immunoresponsive 1 homolog | 35 | 3 h | - | x | 0/9 |
| BATF3 | Basic leucine zipper transcription factor, ATF-like 3 | 35 | 3 h | - | x | 0/11 |
| IL22 | Interleukin-22 | 34 | 3 h | x | x | 0/4 |
| MAOA | Monoamine oxidase A | 33 | 9 h | - | x | 0/11 |
| HPS5 | Hermansky Pudlak syndrome 5 | 30 | 6 h | x | x | 0/10 |
| ETV1 | ETS variant gene 1 | −30 | 3 h | - | - | 0/13 |
| TULP1 | Tubby like protein 1 | 28 | 3 h | - | x | 0/11 |
| MMP1 | Matrix metallopeptidase 1 (interstitial collagenase) | 27 | 3 h | - | x | 1/7 |
| LIPI | Lipase, member I | 26 | 3 h | - | x | 1/9 |
| RPL37 | Ribosomal protein L37 | 26 | 3 h | x | x | 0/9 |
| GBP | Guanylate binding protein | 25 | 3 h | x | x | 0/5 |
| OAS | 2‘5’oligoadenylate synthetase like | 25 | 3 h | x | x | 0/0 |
| SPINK5 | Serine peptidase inhibitor, Kazal type 5 | −25 | 6 h | - | - | 0/7 |
| Mx1 | Myxovirus (influenza virus) resistance-1 | 24 | 3 h | x | x | 1/16 |
| B) | ||||||
| TULP1 | Tubby like protein 1 | 118 | 3 h | - | x | 0/11 |
| IL6 | Interleukin-6 | 67 | 9 h | x | x | 0/8 |
| CMBL | Carboxymethylenebutenolidase homolog | 53 | 3 h | - | x | 0/12 |
| LOC396260 | Mature avidin | 44 | 9 h | - | x | 1/7 |
| LAO | L-amino-acid oxidase precursor | 40 | 3 h | - | x | 0/7 |
| MSC | Musculin (activated B-cell factor-1) | 33 | 3 h | - | x | 0/5 |
| FKBP5 | FK506 binding protein 5 | 30 | 3 h | x | x | 0/6 |
| TGM4 | Transglutaminase 4 (prostate) | 24 | 3 h | - | - | 0/10 |
| LYG2 | Lysozyme G-like 2 | 24 | 3 h | - | x | 0/6 |
| BATF3 | Basic leucine zipper transcription factor, ATF-like 3 | 22 | 3 h | - | x | 0/11 |
| GBP | Guanylate binding protein | 22 | 3 h | x | x | 0/5 |
| RPL37 | Ribosomal protein L37 | 20 | 3 + 9 h | x | x | 0/9 |
| IFIT-5 | Interferon induced protein with tetratricopeptide repeats 5 | 18 | 3 + 9 h | x | x | 1/9 |
| IRG1 | Immunoresponsive 1 homolog | 19 | 9 h | - | x | 0/9 |
| TLR5 | Toll-like receptor-5 | −18 | 3 h | x | - | 0/11 |
| SEMA6D | −17 | 3 h | - | x | 0/11 | |
| GCH1 | GTP cyclohydrolase 1 | 17 | 3 h | x | x | 0/9 |
| GAL9 | Gallicin 9 | 16 | 3 h | - | - | 0/8 |
| Rd | Riboflavin-binding protein | 16 | 3 h | - | - | 0/15 |
| MAOA | Monoamine oxidase A | 16 | 9 h | - | x | 0/11 |
| SAMD9L | Sterile alpha motif domain containing 9 like | 15 | 3 + 9 h | x | x | 0/13 |
| K203 | Chicken chemokine (C-C motif) L i 3 | 14 | 9 h | - | x | 0/6 |
| IL1RL1 | Interleukin-1 receptor like 1 | 14 | 3 h | x | x | 0/15 |
| MX1 | Myxovirus (influenza virus) resistance-1 | 13 | 3 + 6 + 9 h | x | x | 1/16 |
| SOCS3 | Suppressor of cytokine signaling 3 | 12 | 9 h | x | x | 1/9 |
| RASD1 | RAS, dexamethasone induced 1 | 12 | 3 h | - | x | 0/3 |
| OAS | 2‘5’oligoadenylate synthetase like protein | 11 | 3 h | x | x | 0/0 |
| ALB | Albumin | 10 | 3 h | - | - | 0/12 |
| PDK4 | Pyruvate dehydrogenase kinase, isozyme 4 | 10 | 3 h | x | x | 0/12 |
| SNAP25 | Synaptosomal-associated protein, 25 kDa | −10 | 3 h | x | - | 0/19 |
Number and portion of chicken genes containing ISRE and/or GAS motifs
| Input | Localisation | ISRE/GAS | Percent | |
|---|---|---|---|---|
| Not sign. after IFN | 9677 | whole gene | 87/2117 | 22 |
| 6 kb upstream | 10/406 | 4 | ||
| cIRG | 383 | whole gene | 3/94 | 25 |
| 6 kb upstream | 3/20 | 6 | ||
| nIRG | 2254 | whole gene | 13/575 | 26 |
| 6 kb upstream | 3/102 | 5 |
Regions analysed were either 6 kb upstream of the first exon of the respective gene referred to as “6 kb upstream” or from 6 kb upstream of the first exon down to the last exon of the gene sequence, referred to as “whole gene”
Fig. 4IRGs exhibit different expression profiles. a MEV analysis of genes with differential expression after 3 h identified nine different groups of expression profiles over the three sampling time points. Shown are characteristic examples for each group with gene name and tissue (S for spleen, L for lung) for which the profile was found. b Comparison of profiles for Mx, OAS and PKR in spleen (black symbols) and lung (grey symbols)
Expression profiles identified by MeV. Shown are the numbers of genes assigned to the different clusters (see Fig. 4a), subdivided into cIRGs and nIRGs and the respective tissues
| Expression | # of genes | cIRGs | nIRGs | ||
|---|---|---|---|---|---|
| Spleen | Lung | Spleen | Lung | ||
| 1 | 900 | 139 | 59 | 462 | 240 |
| 2 | 798 | 52 | 23 | 543 | 180 |
| 3 | 317 | 35 | 63 | 108 | 111 |
| 4 | 399 | 28 | 5 | 319 | 47 |
| 5 | 156 | 29 | 4 | 57 | 66 |
| 6 | 38 | 3 | 2 | 31 | 2 |
| 7 | 39 | 0 | 7 | 8 | 24 |
| 8 | 20 | 1 | 0 | 19 | 0 |
| 9 | 98 | 2 | 28 | 8 | 60 |
Fig. 5Validation of array results. a Comparison of detected fold changes for IL6 mRNA from the microarray experiment and qRT-PCR on identical samples. b Amount of IL6 protein in plasma samples of IFN treated and untreated animals
Fig. 6Gene ontology of differentially expressed genes. Differentially expressed genes with an FC of at least ± 3 were subjected to Panther gene ontology. Shown are identified biological processes and their percental distribution between genes with higher (+) and lower (-) mRNA abundance after IFN injection in spleen and lung
KEGG Pathway Express analysis
| Spleen | Lung | |||||||
|---|---|---|---|---|---|---|---|---|
| Pathway name | Rank | Impact factor | input genes/genes in pathway | corrected gamma | Rank | Impact factor | input genes/genes in pathway | corrected gamma |
| Leukocyte transendothelial migration | 1 | 138.9 | 16/119 |
| 52 | 3.1 | 7/119 | 0.190507 |
| Cell adhesion molecules (CAMs) | 2 | 123.4 | 15/134 |
| 54 | 2.9 | 7/134 | 0.209069 |
| Phosphatidylinositol signaling system | 21 | 5.7 | 6/76 | 0.02196 | 1 | 27.5 | 7/76 |
|
| Jak-STAT signaling pathway | 3 | 16.0 | 32/155 | 2.00E-06 | 2 | 18.7 | 24/155 |
|
| Toll-like receptor signaling pathway | 4 | 14.9 | 24/102 | 5.22E-06 | 3 | 17.2 | 19/102 |
|
| Circadian rhythm | 11 | 8.5 | 3/13 | 0.00192 | 4 | 17.1 | 1/13 |
|
| Graft-versus-host disease | 5 | 14.4 | 6/42 |
| 7 | 11.7 | 6/42 | 1.02E-04 |
| Pathways in cancer | 6 | 13.6 | 63/330 |
| 5 | 13.4 | 39/330 | 2.19E-05 |
| Complement and coagulation cascades | 31 | 4.0 | 11/69 | 0.08904 | 6 | 12.7 | 13/69 |
|
| Axon guidance | 7 | 12.4 | 30/129 |
| 49 | 3.2 | 9/129 | 0.174755 |
| Bladder cancer | 8 | 11.7 | 14/42 |
| 35 | 3.9 | 5/42 | 0.098477 |
| Hematopoietic cell lineage | 9 | 11.6 | 17/87 |
| 9 | 8.5 | 11/87 | 0.001957 |
| MAPK signaling pathway | 10 | 10.9 | 44/272 |
| 24 | 4.7 | 19/272 | 0.052229 |
| TGF-beta signaling pathway | 35 | 3.8 | 13/87 | 0.10746 | 8 | 8.9 | 13/87 |
|
| ECM-receptor interaction | 12 | 7.9 | 20/84 | 0.00334 | 10 | 8.1 | 13/84 |
|
| Type II diabetes mellitus | 22 | 5.6 | 7/45 | 0.02363 | 11 | 8.0 | 7/45 |
|
| Long-term depression | 13 | 7.8 | 17/75 |
| 44 | 3.2 | 2/75 | 0.170290 |
| Calcium signaling pathway | 38 | 3.7 | 23/182 | 0.11330 | 13 | 7.6 | 17/182 |
|
| Type I diabetes mellitus | 14 | 7.5 | 8/44 |
| 12 | 7.6 | 6/44 | 0.004176 |
| Adherens junction | 15 | 7.0 | 11/78 |
| 33 | 4.0 | 3/78 | 0.091871 |
| Allograft rejection | 16 | 7.0 | 7/38 |
| 15 | 6.7 | 5/38 | 0.009661 |
| Epithelial cell signaling in Helicobacter pylori infection | 17 | 6.9 | 15/68 |
| 16 | 6.4 | 9/68 | 0.011897 |
| Apoptosis | 25 | 5.5 | 15/89 | 0.02658 | 14 | 6.8 | 11/89 |
|
| Amyotrophic lateral sclerosis (ALS) | 18 | 6.4 | 10/56 |
| 39 | 3.6 | 5/56 | 0.123832 |
| Focal adhesion | 19 | 6.2 | 35/203 |
| 34 | 4.0 | 17/203 | 0.095007 |
| Small cell lung cancer | 20 | 6.0 | 18/86 |
| 30 | 4.1 | 9/86 | 0.083372 |
| Systemic lupus erythematosus | 26 | 5.4 | 10/144 | 0.02984 | 17 | 5.7 | 7/144 |
|
| GnRH signaling pathway | 23 | 5.6 | 18/103 |
| 32 | 4.1 | 8/103 | 0.085545 |
| PPAR signaling pathway | 24 | 5.6 | 14/70 |
| - | - | - | - |
| Long-term potentiation | 41 | 3.3 | 11/73 | 0.15896 | 19 | 5.4 | 5/73 |
|
Shown are the 30 most significantly affected pathways in spleen and lung ranked according to their corrected gamma p-value (the value which was used for the ranking is shown in bold letters); “Rank” is the rank of a pathway among all significantly affected pathways according to its impact factor; the “Impact factor” of a pathway is calculated from a probabilistic term considering the proportion of differentially regulated genes on the pathway and gene perturbation factors of all genes in the pathway [46]
Fig. 7Multilayer interaction of differentially expressed genes. IPA network analysis demonstrating gene interactions with the upstream regulators PTX3 (a) and Albumin (b). Genes with higher mRNA abundance in the IFN treated animals are shown in red, genes with lower mRNA abundance in the treated animals in green. The small diagrams next to each differentially expressed gene display expression (FC) at the different time points. The magnification shows the expression course for IL6
Fold expression of differentially expressed chemokines and chemokine receptors after IFN treatment
| Spleen | Lung | |||||
|---|---|---|---|---|---|---|
| Gene symbol | IFN (3 h) | IFN (6 h) | IFN (9 h) | IFN (3 h) | IFN (6 h) | IFN (9 h) |
| CCLi3 | 145 | 10 | 5 | 3 | 3 | 14 |
| CCLi6 | 17 | 2 | - | - | - | - |
| CCLi9 | 3 | 5 | 6 | 6 | 11 | 17 |
| CXCL13L2 | 9 | 11 | 13 | 3 | 4 | 7 |
| CCL19 | 6 | 5 | 4 | 13 | 8 | 11 |
| CXCLi2 | 3 | - | - | 2 | 2 | 8 |
| CX3CL1 | 6 | 3 | - | 2 | - | 2 |
| CXCLi1 | 5 | 2 | 2 | 2 | 2 | 5 |
| CXCL13L1 | - | - | 2 | 3 | 3 | 5 |
| CCL20 | 4 | - | - | 2 | - | 2 |
| CCL21 | - | 3 | 3 | 4 | 2 | 2 |
| CCLi4 | 3 | −2 | −2 | 4 | 3 | - |
| CCL17 | 3 | −2 | −4 | 3 | - | - |
| XCL1 | −2 | - | - | - | - | - |
| CXCL12 | −4 | - | - | - | - | - |
| CXCR4 | 5 | - | - | - | - | - |
| CCRa | 2 | 3 | 2 | 4 | 3 | 3 |
| CCR7 | - | - | - | 2 | - | 2 |
| CCR8 | 2 | - | - | - | - | - |
| XCR1 | −2 | - | −2 | - | - | - |
| CXCR7 | - | - | - | −2 | - | −2 |
| CCR6 | −3 | - | −2 | - | - | - |
| CX3CR1 | −5 | - | - | - | - | - |
Fig. 8Tissue and time specific expression profiles for chemokines and cytokines. Fold expression of differentially expressed chemokines (a + b) and cytokines (c + d) after IFN injection in the spleen (a + c) and the lung (b + d) in relation to control birds
Fold expression of differentially expressed cytokines and cytokine receptors after IFN treatment
| Spleen | Lung | |||||
|---|---|---|---|---|---|---|
| Gene Symbol | IFN (3 h) | IFN (6 h) | IFN (9 h) | IFN (3 h) | IFN (6 h) | IFN (9 h) |
| IL6 | 186 | 10 | 11 | 7 | 12 | 67 |
| CSF3 | 58 | - | - | - | - | 7 |
| IL22 | 34 | - | 3 | - | - | 3 |
| IL1B | 14 | - | - | 4 | 4 | 14 |
| IL18 | 12 | 4 | 3 | 4 | 3 | 4 |
| IFNG | 10 | 2 | 2 | 2 | 3 | 9 |
| CD40 | 8 | 3 | - | - | - | - |
| TNFSF8 | 7 | - | - | - | - | - |
| IL12B | −2 | - | - | 3 | 6 | 4 |
| IL2 | 5 | - | - | 3 | - | 3 |
| IL17F | 5 | - | 2 | - | - | - |
| TNFSF15 | 5 | - | - | - | - | - |
| FAS | 3 | - | - | 3 | - | 2 |
| IL12A | 3 | - | - | - | - | - |
| TNFSF10 | 3 | 3 | - | - | - | - |
| TNFSF13B | - | - | - | 2 | - | - |
| TNFSF11 | - | - | −2 | - | - | - |
| IL7 | −3 | - | - | - | - | - |
| TRAIL | −3 | - | - | - | - | - |
| IL1RL1 | 15 | 5 | 3 | 14 | 3 | 3 |
| IL13RA2 | 13 | 7 | 6 | 14 | 12 | 18 |
| TNFRSF8 | 9 | 3 | 4 | - | - | - |
| IL1R2 | 7 | 3 | - | 3 | - | - |
| TNFRSF11B | 3 | - | - | 5 | - | - |
| CSF3R | - | 4 | 4 | - | 2 | 2 |
| IL20RA | 4 | 3 | - | 3 | - | - |
| CSF2RB | 4 | - | - | 3 | - | 2 |
| IL2RA | 4 | - | - | - | - | 2 |
| IL23R | 4 | 2 | - | - | - | - |
| CSF2RA | 3 | 2 | - | 3 | 3 | 3 |
| IL10RB | 3 | - | - | 2 | - | - |
| TNFRSF1B | 3 | - | - | 2 | - | - |
| IL21R | 2 | - | - | 3 | - | - |
| TNFRSF1A | - | - | - | 2 | - | 3 |
| IFNGR1 | 3 | - | - | - | - | - |
| IL4R | 3 | - | - | - | - | - |
| IL1R1 | 3 | - | - | - | - | - |
| IFNAR1 | 2 | - | - | 2 | - | - |
| TNFRSF13C | 2 | - | - | - | - | - |
| IL7R | 2 | - | - | - | - | - |
| IL10RA | 2 | - | - | - | - | - |
| IL12RB2 | −2 | - | - | - | - | - |
| IL28RA | −2 | - | - | - | - | - |
| IL1RL2 | - | −2 | −2 | - | - | - |
| IL11RA | −3 | - | - | - | - | - |